205 related articles for article (PubMed ID: 17571370)
1. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Kudo Y; Komuro I; Akazawa H
Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
[No Abstract] [Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of heart failure. 2 neurohormone blockers are enough].
MMW Fortschr Med; 2002 Sep; 144(35-36):57. PubMed ID: 12380364
[No Abstract] [Full Text] [Related]
4. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Kageyama S
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
[No Abstract] [Full Text] [Related]
5. [AT 1-blocker can be given in addition to ACE inhibitor and beta blocker. "Triple therapy decidedly well tolerated even in severe heart failure"].
Dietz R
MMW Fortschr Med; 2004 May; 146(22):50. PubMed ID: 15373115
[No Abstract] [Full Text] [Related]
6. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Sarzani R; Dessì-Fulgheri P
J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
[No Abstract] [Full Text] [Related]
7. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
8. [Angiotensin receptor blockers in heart failure. CHARM Study].
Kochsiek K
Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
[No Abstract] [Full Text] [Related]
9. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Hennekens CH; Kowalczykowski M; Hollar D
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
[TBL] [Abstract][Full Text] [Related]
10. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
11. Combination of ARB and ACE inhibitors in heart failure patients.
Wexler R; Feldman D
Am Fam Physician; 2009 Mar; 79(6):454; author reply 456. PubMed ID: 19323357
[No Abstract] [Full Text] [Related]
12. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
[No Abstract] [Full Text] [Related]
13. [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Mitsuyama S
Nihon Rinsho; 2007 May; 65 Suppl 5():78-83. PubMed ID: 17571369
[No Abstract] [Full Text] [Related]
14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
15. [Hyperkalemia, heart failure and reduced renal function].
Bugge JF
Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1354-5. PubMed ID: 20596118
[No Abstract] [Full Text] [Related]
16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
[TBL] [Abstract][Full Text] [Related]
17. [AT1 blockers against heart failure. The charm of polypharmacy].
MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
[No Abstract] [Full Text] [Related]
18. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Kubota T; Takeshita A
Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
[TBL] [Abstract][Full Text] [Related]
19. [New options against undertreatment].
Pfeffer M
MMW Fortschr Med; 2003 Dec; 145(49):18. PubMed ID: 14963987
[No Abstract] [Full Text] [Related]
20. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Yasumura Y; Miyatake K; Okamoto H; Miyauchi T; Kawana M; Tsutamoto T; Kitakaze M; Matsubara H; Takaoka H; Anzai T; Himeno H; Yokoyama H; Yokoya K; Shintani U; Hashimoto K; Koretsune Y; Nakamura Y; Imai K; Maruyama S; Masaoka Y; Sekiya M; Shiraki T; Shinohara H; Ozono K; Matsuoka T; Miyao Y; Nomura F
Circ J; 2004 Apr; 68(4):361-6. PubMed ID: 15056835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
